RAP 0.00% 20.5¢ resapp health limited

Ann: Breakthrough Performance in Paediatric Clinical Study, page-35

  1. 938 Posts.
    lightbulb Created with Sketch. 8
    From the Ann. " This clearly demonstrates that ResApps diagnostic tool outperforms experienced clinicians using stethoscopes and can match the results provided by an entire suite of expensive, time-consuming clinical tests".......this is going to be a monster IMO
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.